GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients
Trial statusRecruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexFemale
Age18-45
SponsorXiaojun Chen
About this trial
To investigate the efficacy of GnRHa plus letrozole in obese progestin-insensitive EEC patients.
Eligibility criteria
Qualifiers
Have a confirmed initial pathological diagnosis based upon hysteroscopy: histologically prove well-differentiated EEC G1 without myometrial invasion
BMI≥30kg/m2
No signs of suspicious extrauterine involvement on enhanced magnetic resonance imaging (MRI) or enhanced computed tomography (CT) or ultrasound
Megestrol acetate ≥ 160 mg qd using, combined with Levonorgestrel Lntrauterine System (LNG-IUS) inserted or not
Disqualifiers
Combined with severe medical disease or severely impaired liver and kidney function
Pathologically confirmed as endometrial cancer with suspicious myometrial invasion or extrauterine metastasis
Patients with other types of endometrial cancer or other malignant tumors of the reproductive system
Patients with breast cancer or other hormone- dependent tumors or diseases that cannot be used with GnRHa or Letrozole
Trial design
Treatments tested in this trial
- GnRH antagonist
- Letrozole 2.5mg
Treatment groups
29 Participants
are divided into 1 treatment groupSponsors and collaborators
Xiaojun Chen
Lead sponsor
Fudan University
Sponsor institution
Source ClinicalTrials.gov